Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
Highlights
– Clofutriben, a selective 11β‑HSD1 inhibitor, attenuated many biomarker signals of prednisolone‑related toxicity across tested doses in patients with polymyalgia rheumatica (PMR).
– When combined with clofutriben, prednisolone 10 mg/day produced clinical relapses in some patients; increasing prednisolone to 20–30 mg/day restored symptom control without losing toxicity mitigation.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.